ObsEva To Present Phase 3 IMPLANT 2 Clinical Trial Results Of Nolasiban In IVF

(RTTNews) - ObsEva SA (OBSV), a Swiss clinical-stage biopharmaceutical company focused on woman's reproductive health and pregnancy, announced Friday that the Phase 3 IMPLANT 2 clinical trial results of Nolasiban in IVF.

The re4sults will be presented at the 74th annual meeting of the American Society of Reproductive Medicine or ASRM during October 6-10.

ObsEva said the presentation has been awarded the Prize Paper of the Society for Assisted Reproductive Technology or SART.

IMPLANT 2 is a Phase 3, randomized, double blind, clinical trial designed to confirm the efficacy of nolasiban to increase the chance of pregnancy and live birth in patients undergoing IVF or ICSI.

Following ovarian stimulation, egg retrieval and fertilization, eligible women were randomized to receive either a single, oral dose of 900 mg nolasiban or placebo, 4 hours before Day 3 or Day 5 fresh, single embryo transfer (SET).

The primary endpoint was ongoing pregnancy at 10 weeks after SET. Women with confirmed pregnancies were monitored until delivery, with a key secondary endpoint being live birth, and the infants are being followed-up for 6 months.